Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.95 EUR | +0.72% | +5.75% | +24.16% |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
Mar. 07 | Van Lanschot Kempen Plans Early Redemption of EUR100 Million Notes | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 909.9 | 881.4 | 1,477 | - | - |
Enterprise Value (EV) 1 | 909.9 | 881.4 | 1,477 | 1,477 | 1,477 |
P/E ratio | 6.57 x | 11.5 x | 13.2 x | 12 x | 11.3 x |
Yield | 9.09% | 7.99% | 7.58% | 5.88% | 6.19% |
Capitalization / Revenue | 1.53 x | 1.47 x | 2.15 x | 2.08 x | 2.01 x |
EV / Revenue | 1.53 x | 1.47 x | 2.15 x | 2.08 x | 2.01 x |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | 1.21 x | 1.16 x | 1.12 x |
Nbr of stocks (in thousands) | 41,360 | 40,247 | 42,262 | - | - |
Reference price 2 | 22.00 | 21.90 | 34.95 | 34.95 | 34.95 |
Announcement Date | 2/24/22 | 2/23/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | 594.7 | 599.7 | - | 685.7 | 709.6 | 733.7 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | 173.5 | 146.6 | - | 180.1 | 184.6 | 196.1 |
Operating Margin | - | 29.17% | 24.45% | - | 26.26% | 26.02% | 26.73% |
Earnings before Tax (EBT) 1 | - | 178.5 | - | - | 159.8 | 173.9 | 185.3 |
Net income 1 | 43.01 | 143.8 | 84.3 | 125.2 | 114.5 | 124.2 | 131.5 |
Net margin | - | 24.18% | 14.06% | - | 16.7% | 17.51% | 17.92% |
EPS 2 | 1.050 | 3.350 | 1.900 | - | 2.640 | 2.905 | 3.105 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | 2.000 | 1.750 | - | 2.650 | 2.055 | 2.165 |
Announcement Date | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|
Net sales 1 | 269.3 | 325.4 | 293.1 | 306.6 | 315.7 | 349.5 | 349.5 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | 68.8 | 104.7 | 69.5 | 77.1 | 73.4 | 91.4 | 88.7 |
Operating Margin | 25.55% | 32.18% | 23.71% | 25.15% | 23.25% | 26.15% | 25.38% |
Earnings before Tax (EBT) 1 | 74 | 104.5 | 60.6 | - | 71.3 | 85 | 83.6 |
Net income 1 | 58.3 | 85.5 | - | - | 48.4 | 59.1 | 58.3 |
Net margin | 21.65% | 26.28% | - | - | 15.33% | 16.91% | 16.68% |
EPS 2 | 1.339 | 2.010 | 1.112 | - | 1.170 | 1.390 | 1.370 |
Dividend per Share 2 | - | 2.000 | - | 1.750 | - | - | 2.000 |
Announcement Date | 8/26/21 | 2/24/22 | 8/25/22 | 2/23/23 | 8/24/23 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | 12.5% | 6.04% | - | 9.1% | 9.55% | 10.2% |
ROA (Net income/ Total Assets) | - | 0.87% | 0.51% | - | 0.69% | 0.7% | 0.74% |
Assets 1 | - | 16,510 | 16,663 | - | 16,596 | 17,750 | 17,765 |
Book Value Per Share 2 | - | - | - | - | 28.90 | 30.10 | 31.20 |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.16% | 1.59B | |
+5.85% | 8.84B | |
+11.57% | 3.41B | |
-34.52% | 3.06B | |
+13.39% | 2.53B | |
+16.02% | 2.42B | |
+41.00% | 2.15B | |
+14.09% | 1.51B | |
+9.10% | 1.44B | |
+0.85% | 1.04B |
- Stock Market
- Equities
- VLK Stock
- Financials Van Lanschot Kempen N.V